jRCT2071240067已完成不适用
A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants (J4X-JE-LWCA)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 59
- 主要终点
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Basic Science
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 55age old under（—）
- 性别
- All
入选标准
- •Japanese participants who are overtly healthy as determined by medical evaluation including medical history and physical examination
- •Have a body mass index within the range 18 to 30 kilogram per square meter (kg/m2)
- •Have a body weight of:
- •>= 40 kilograms (kg) for individuals assigned female at birth
- •>= 50 kg for individuals assigned male at birth
排除标准
- •Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, or convulsions that, in the judgment of the investigator, indicate a medical problem that would preclude study participation
- •Have an abnormality in the 12-lead echocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
- •Have a history of clinically significant multiple or severe drug allergies or severe posttreatment hypersensitivity reactions, which in the opinion of the investigator may hamper participation in the study
- •Show evidence of hepatitis C and/or have a positive hepatitis C virus antibody test
- •Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antigen and/or antibodies.
- •Show evidence of hepatitis B and/or positive hepatitis B surface antigen
- •Show evidence of syphilis or have a positive syphilis test.
- •Have an abnormal blood pressure (supine) as determined by the investigator
- •Are pregnant or intend to become pregnant or to breastfeed during the study.
- •Participants with a history of drug abuse which, in the opinion of the investigator, is clinically significant or who test positive for drugs of abuse at screening or admission
- •Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator
- •Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes
- •Are unwilling to comply with the dietary restrictions required for this study
结局指标
主要结局
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
时间窗: Baseline to 12 Days
Part B: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
PK: Maximum Concentration (Cmax) of Rosuvastatin
时间窗: Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: Cmax of Rosuvastatin
PK: Area Under the Concentration Versus Time Curve (AUC) of Rosuvastatin
时间窗: Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: AUC of Rosuvastatin
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
A Study of LY3549492 in Japanese Participants with Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
(J3H-JE-GZNG )jRCT2071240136Eli Lilly Japan K.K.90
未知
1 期
A Phase 1 Study of LY2584702 in Japanese Patients with Solid TumorsCancerJPRN-jRCT2080221292Eli Lilly Japan K.K.
未知
1 期
A Phase 1 Study of LY2606368 in Japanese Patients with Advanced Solid TumorseoplasmJPRN-jRCT2080222962Eli Lilly Japan K.K.
未知
1 期
A Phase 1 Study of LY2940680 in Japanese Patients with Advanced Solid Tumorseoplasm MetastasisJPRN-jRCT2080222179Eli Lilly Japan K.K.
已完成
1 期
A Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors I6F-JE-JJCCAdvanced Solid TumorJPRN-jRCT2080223309Eli Lilly Japan K.K.